Oncology News | pharmaphorum

News

Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.

News

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.

News

Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.

News

Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan.

News

BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form.

News

AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.